Assignee
ETUBICS CORP
US·17 granted patents·8 pending applications·44 citations·filing 2012–2024
Top patents by PatentIndex Score
25 records- 0197US11504423B2Methods and compositions for producing an adenovirus vector for use with multiple vaccinationsETUBICS CORP·Filed 2022·Granted Nov 22, 2022·2 cites·18 claims
- 0295US11826417B2Methods and compositions for producing an adenovirus vector for use with multiple vaccinationsETUBICS CORP·Filed 2022·Granted Nov 28, 2023·1 cites·19 claims
- 0395US11529408B2Methods and compositions for producing an adenovirus vector for use with multiple vaccinationsETUBICS CORP·Filed 2022·Granted Dec 20, 2022·1 cites·19 claims
- 0495US11389521B2Methods and compositions for producing an adenovirus vector for use with multiple vaccinationsETUBICS CORP·Filed 2020·Granted Jul 19, 2022·3 cites·18 claims
- 0593US10695417B2Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoproteinETUBICS CORP·Filed 2016·Granted Jun 30, 2020·9 cites·25 claims
- 0692US12370250B2Methods and compositions for producing an adenovirus vector for use with multiple vaccinationsETUBICS CORP·Filed 2024·Granted Jul 29, 2025·0 cites·19 claims
- 0792US11376316B2Breast cancer vaccines and methods of use thereofETUBICS CORP·Filed 2016·Granted Jul 5, 2022·3 cites·14 claims
- 0892US11369673B2HPV vaccines and methods of use thereofETUBICS CORP·Filed 2016·Granted Jun 28, 2022·3 cites·16 claims
- 0991US11104916B2Compositions and methods for alphavirus vaccinationETUBICS CORP·Filed 2017·Granted Aug 31, 2021·6 cites·17 claims
- 1091US10563224B2Replication defective adenovirus vector in vaccinationETUBICS CORP·Filed 2017·Granted Feb 18, 2020·5 cites·18 claims
- 1190US11344613B2Sequential administration of a replication defective adenovirus vector in vaccination protocolsETUBICS CORP·Filed 2012·Granted May 31, 2022·3 cites·16 claims
- 1288US2023364218A1Methods and compositions for producing an adenovirus vector for use with multiple vaccinationsETUBICS CORP·Filed 2023·Application pending·0 cites
- 1387US11304998B2Combination immunotherapies comprising IL-15 superagonistsETUBICS CORP·Filed 2021·Granted Apr 19, 2022·1 cites·9 claims
- 1483US11149087B2Methods and compositions for combination immunotherapyETUBICS CORP·Filed 2016·Granted Oct 19, 2021·2 cites·25 claims
- 1581US11116827B2Compositions and methods for tumor vaccination and immunotherapy involving HER antigensETUBICS CORP·Filed 2018·Granted Sep 14, 2021·1 cites·14 claims
- 1681US11020467B2Combination immunotherapies comprising IL-15 superagonistsETUBICS CORP·Filed 2018·Granted Jun 1, 2021·1 cites·10 claims
- 1779US10835596B2Compositions and methods for flavivirus vaccinationETUBICS CORP·Filed 2017·Granted Nov 17, 2020·2 cites·16 claims
- 1867US2021138056A1Neoepitope vaccine compositions and methods of use thereofETUBICS CORP·Filed 2021·Application pending·0 cites
- 1964US11352642B2Methods and compositions for combination immunotherapyETUBICS CORP·Filed 2016·Granted Jun 7, 2022·1 cites·14 claims
- 2058US2020282032A1Neoepitope vaccine compositions and methods of use thereofETUBICS CORP·Filed 2017·Application pending·0 cites
- 2144US2019022209A1Methods and compositions for influenza vaccinationETUBICS CORP·Filed 2017·Application pending·0 cites
- 2243US2019125852A1Compositions and methods for tumor vaccination using prostate cancer-associated antigensETUBICS CORP·Filed 2017·Application pending·0 cites
- 2343US2019134195A1Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseasesETUBICS CORP·Filed 2017·Application pending·0 cites
- 2442US2019134174A1Compositions and methods for tumor vaccination and immunotherapy involving her2/neuETUBICS CORP·Filed 2017·Application pending·0 cites
- 2540US2019030151A1Methods and compositions for t-cell immunotherapyETUBICS CORP·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ETUBICS CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →